(PDF) P1.13-42 Activity of Novel HER2 Inhibitor,

P1.13-42 Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.899

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-96 Clinical Characteristics of Non–Small Cell Lung Cancer Harboring Mutations in Exon 20 of EGFR or HER2

Journal of Thoracic Oncology

Respiratory Medicine

English

P088 Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Clinical Cancer Research

Cancer Research

English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

English

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Cancer Research

English

Lung Adenocarcinoma Manifesting With Lymphangitic Spread and Psammoma Bodies, Harboring a HER2 Exon 20 Insertion Mutation (p.A745_G746insYVMA)

Journal of Thoracic Oncology

Respiratory Medicine

English

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Cancer Research

Cancer Research

English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer

Cancer Research

English